Contact the team

The PEXIVAS Trial Team are always here to help. For further information about the PEXIVAS trial please contact us.

General Enquiries

For queries about collection of data and data analysis please contact the Birmingham Clinical Trials Unit (BCTU):


Postal address:
PEXIVAS Trial Office
Birmingham Clinical Trials Unit (BCTU)
Institute of Applied Health Research
College of Medical and Dental Sciences
Public Health Building
University of Birmingham
B15 2TT

Fax: +44 (0)121 415 9135


Elizabeth Brettell  Trials Manager +44 (0)121 415 9130
Emma Barsoum  Trial Co-ordinator +44 (0)121 415 9132
Noreen Akhtar  Trial Administrator +44 (0)121 415 9134
Charmaine Hunt  Trial Administrator +44 (0)121 415 9132
Terry Hughes  Data Manager +44 (0)121 415 9131

PEXIVAS Chief Investigators

Dr David Jayne (Cambridge University Hospitals NHS Foundation Trust, United Kingdom)

Dr Peter A. Merkel (Boston University Medical School, Boston, USA)

Dr Michael Walsh (McMaster University Heath Science Centre, Hamilton, Canada)

Worldwide PEXIVAS Study Offices


Dr David Jayne, Elizabeth Broadhurst and Biljana Brezina, Vasculitis Research Office, Box 118/Box 246, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ, United Kingdom, Tel: 01223 217259, Fax: 01223 586796.


Dr Peter Merkel and Carol A. McAlear, Vasculitis Center, E5, Boston University School of Medicine, 72 East Concord Street E533, Boston, MA, 02118, USA, Tel: +01 617 414 2501, Fax: +01 617 414 2510.


Dr. Michael Walsh, Department of Clinical Epidemiology and Biostatistics, Room 2C9, 1200 West Street Main, McMaster University Health Science Centre, Hamilton, Ontario, L8N 3Z5, Canada, Tel: +1 905 525 9140 ext 22876, Fax: +1 905 524 3841.


Chen Au Peh and Carmel Hawley, University of Queensland, Level 1, Building 33, Princess Alexandra Hospital, Ipswich Rd, Wooloongabba, QLD 4102, Australia, Phone: +61 732402625.

Find out more information about our other renal trials

The University of Birmingham Clinical Trials Unit (BCTU) is a Research Unit in the School of Medicine specialising in the design, conduct and analysis of clinical trials.

Accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease: prospective longitudinal study in a multi-ethnic population.

GloMY is a national, multi-centre, randomised controlled open-label pilot trial of Myfortic plus short course steroids versus standard care in patients with proteinuric primary focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).

Long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of childhood nephrotic syndrome: national multicentre randomised double blind trial

Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome.

STOP-ACEi is a multi-centre, randomised controlled trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced kidney disease.

Eculizumab in Shiga-Toxin producing E. Coli Haemolytic Uraemic Syndrome (ECUSTEC): A Randomised, Double Blind, Placebo-Controlled Trial.